Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation.
Humans
Decitabine
Acetylcysteine
/ therapeutic use
Busulfan
Prospective Studies
Reactive Oxygen Species
Myeloproliferative Disorders
/ complications
Hematopoietic Stem Cell Transplantation
/ methods
Behavior Therapy
Neoplasms
/ complications
Transplantation Conditioning
/ adverse effects
Leukemia, Myeloid, Acute
/ therapy
Graft vs Host Disease
/ etiology
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
26
02
2023
received:
10
01
2023
accepted:
02
03
2023
medline:
15
5
2023
pubmed:
8
3
2023
entrez:
7
3
2023
Statut:
ppublish
Résumé
Conditioning therapy is an essential procedure prior to hematopoietic stem cell transplant (HSCT), imposing a great impact on the outcomes of recipients. We performed a prospective randomized controlled trial to assess the outcome of HSCT recipients with myeloid malignancies after receiving the conditioning therapy consisting of modified BUCY (mBUCY), N-acetyl-L-cysteine (NAC), and decitabine. Enrolled patients were randomly allocated to either Arm A (decitabine, day -12 to -10; NAC, day -9 to +30; mBUCY, day -9 to -2), or Arm B (mBUCY regimen followed by stem cells infusion). Seventy-six patients in Arm A and 78 patients in Arm B were finally evaluated. The results showed platelet recovery accelerate in Arm A, with more patients achieving a platelet count of ≥50 × 10
Substances chimiques
Decitabine
776B62CQ27
Acetylcysteine
WYQ7N0BPYC
Busulfan
G1LN9045DK
Reactive Oxygen Species
0
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
881-889Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Castagnoli R, Delmonte OM, Calzoni E, Notarangelo LD. Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives. Front Pediatr. 2019;7:295.
Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70:1382-1388.
Socié G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total- body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001;98:3569-3574.
Ruutu T, van der Werf S, van Biezen A, et al. Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019;54:2013-2019.
Xu L, Chen H, Chen J, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol. 2018;2:33.
Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol. 2018;107(2):138-150.
Gao L, Zhang Y, Wang S, et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial. J Clin Oncol. 2020;20:4249-4259.
Tang X, Valdez BC, Ma Y, et al. Low-dose decitabine as part of a modified Bu-cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2021;56(7):1674-1682.
Li Y, Cheng L, Xu C, et al. A retrospective observation of treatment outcomes using decitabine-combined standard conditioning regimens before transplantation in patients with relapsed or refractory acute myeloid leukemia. Front Oncol. 2021;11:702239.
Mohrin M. Mito-managing ROS & redox to reboot the immune system: tapping mitochondria & redox management to extend the reach of hematopoietic stem cell transplantation. Free Radic Biol Med. 2021;165:38-53.
Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med. 2006;12:446-451.
Pasha A, Calvani M, Favre C. β3-Adrenoreceptors as ROS balancer in hematopoietic stem cell transplantation. Int J Mol Sci. 2021;11:2835.
Ludin A, Gur-Cohen S, Golan K, et al. Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment. Antioxid Redox Signal. 2014;21(11):1605-1619.
Shinohara A, Imai Y, Nakagawa M, Takahashi T, Ichikawa M, Kurokawa M. Intracellular reactive oxygen species mark and influence the megakaryocyte-erythrocyte progenitor fate of common myeloid progenitors. Stem Cells. 2014;32:548-557.
Hu L, Zhang Y, Miao W, Cheng T. Reactive oxygen species and Nrf2: functional and transcriptional regulators of hematopoiesis. Oxid Med Cell Longev. 2019;2019:5153268.
Mantel CR, O'Leary HA, Chitteti BR, et al. Enhancing hematopoietic stem cell transplantation efficacy by mitigating oxygen shock. Cell. 2015;161:1553-1565.
Cai Q, Capitano M, Huang X, Guo B, Cooper S, Broxmeyer HE. Combinations of antioxidants and/or of epigenetic enzyme inhibitors allow for enhanced collection of mouse bone marrow hematopoietic stem cells in ambient air. Blood Cells Mol Dis. 2018;71:23-28.
Hu L, Cheng H, Gao Y, et al. Antioxidant N-acetyl-L-cysteine increases engraftment of human hematopoietic stem cells in immune-deficient mice. Blood. 2014;13:e45-e48.
Saad A, de Lima M, Anand S, et al. Hematopoietic cell transplantation, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(5):599-634.
Nevo S, Swan V, Enger C, et al. Acute bleeding after bone marrow transplantation (BMT)-incidence and effect on survival. A quantitative analysis in 1,402 patients. Blood. 1998;91(4):1469-1477.
Cordonnier C, Maury S, Ribaud P, et al. A grading system based on severity of infection to predict mortality in allogeneic stem cell transplant recipients. Transplantation. 2006;82(1):86-92.
Kong Y, Shi MM, Zhang YY, et al. N-acetyl-L-cysteine improves bone marrow endothelial progenitor cells in prolonged isolated thrombocytopenia patients post allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2018;93(7):931-942.
de Jong G, Janssen J, Biemond BJ, et al. Survival of early post hematopoietic stem cell transplantation relapse of myeloid malignancies. Eur J Haematol. 2019;103(5):491-499.
Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120:483-495.
Wang Y, Liu L, Pazhanisamy SK, Li H, Meng A, Zhou D. Total body irradiation causes residual bone marrow injury by induction of persistent oxidative stress in murine hematopoietic stem cells. Free Radic Biol Med. 2010;48:348-356.
Shen H, Yu H, Liang PH, et al. An acute negative bystander effect of γ-irradiated recipients on transplanted hematopoietic stem cells. Blood. 2012;119:3629-3637.
Kong Y, Song Y, Hu Y, et al. Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants. Oncotarget. 2016;7(21):30892-30906.
Kong Y, Wang Y, Zhang YY, et al. Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Adv. 2019;3(8):1303-1317.
Kong Y, Song Y, Tang FF, et al. N-acetyl-L-cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-allotransplant. Br J Haematol. 2018;180(6):863-878.
Tang Y, Chen J, Liu Q, et al. Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial. Blood Adv. 2021;5(5):1250-1258.
Shen B, Ma Y, Zhang H, et al. Risk factors associated with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Blood Sci. 2022;4(2):83-88.
Gore SD, Jones C, Kirkpatrick P. Decitabine. Nat Rev Drug Discov. 2006;5(11):891-892.
Pusic I, Choi J, Fiala MA, et al. Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2015;21:1761-1769.
Han S, Kim YJ, Lee J, et al. Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome. J Hematol Oncol. 2015;8:118.
Han Y, Tang Y, Chen J, et al. Low-dose decitabine for patients with thrombocytopenia following allogeneic hematopoietic stem cell transplantation: a pilot therapeutic study. JAMA Oncol. 2015;1(2):249-251.
Goodyear O, Dennis M, Jilani N, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14):3361-3369.
Schroeder T, Fröbel J, Cadeddu R, et al. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia. 2013;27(9):1910-1913.